Lymphoma Action

JNJ-90009530: A phase 1 trial of JNJ-90009530 in people with relapsed or refractory B cell non-Hodgkin lymphoma

Trial

… for the treatment of B-cell NHLwhich has relapsed, or is refractory after two lines of treatment. It aims to see what … Who can enter Adults with B-cell NHL who have relapsed or refractory disease after at least two treatments may be … which has returned after (relapsed) or not responded to (refractory) treatment. You can share the following …

ELM-2: a phase 2 trial assessing the safety of odronextamab in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

Trial

… lymphoma has relapsed or not responded to treatment (refractory lymphoma). The types of B-cell non-Hodgkin … the activity of odronetamab in people with relapsed or refractory B-cell non-Hodgkin lymphoma. You can share the … the safety of odronextamab in adults with relapsed or refractory B-cell non-Hodgkin lymphoma …

KT-413: A trial testing KT-413 in people with relapsed or refractory B-cell Non-Hodgkin lymphoma

Trial

… and well tolerated the medication KT-413 is in relapsed or refractory NHL, as well as the pharmacokinetics and … the medication KT-413 in adults with relapsed or refractory non-Hodgkin lymphoma (NHL) . You can share the … KT-413: A trial testing KT-413 in people with relapsed or refractory B-cell Non-Hodgkin lymphoma …

ALLCAR19: A phase 1 trial of CAR T-cell therapy in adults with relapsed or refractory DLBCL, CLL, SLL, FL or MCL

Trial

… lymphoma (MCL) who have relapsed after, or not responded (refractory) to, previous treatment. Everybody who takes part … future. Who can enter People aged over 16 with relapsed or refractory DLBCL, CLL/SLL, FL or MCL may be eligible for this … A phase 1 trial of CD19 CAR-T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), chronic …

CC-99282: A phase 1 trial of CC-99282 alone and in combination with anti-lymphoma agents in people with relapsed or refractory non-Hodgkin lymphoma

Trial

… back (relapsed) or not responded to previous treatment (refractory). This is a phase 1 (early phase) trial . Little … non-Hodgkin Lymphoma (NHL) which has relapsed or become refractory to treatment may be eligible for this trial. … 1/2 trial evaluating CC-99282 in people with relapsed or refractory non-Hodgkin lymphoma. You can share the following …

P+R-ICE: A phase 2 trial of pembrolizumab with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

Trial

… back (relapsed) or not responded to previous treatment (refractory). Participants will be randomly allocated to one … with R-ICE chemotherapy in people with relapsed or refractory diffuse large B-cell (DLBCL). You can share the … trial of pembrolizumab with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma …

EPCORE CLL-1: A trial testing epcoritamab in people with relapsed or refractory chronic lymphocytic leukaemia and Richter’s syndrome

Trial

… with other medications in patients with relapsed or refractory CLL or Richter’s syndrome. Epcoritamab is an … has come back after ( relapsed ) or not responded to ( refractory ) treatment. You can share the following … A trial testing epcoritamab in people with relapsed or refractory chronic lymphocytic leukaemia and Richter’s …

NX-5948-301: A phase 1 study of a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma

Trial

… lymphoma that has not responded to previous treatment (refractory) or has come back (relapsed) after treatment. … a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma. You can share the following … a new treatment called NX-5948 in adults with relapsed or refractory B-cell lymphoma …

Athena 1: A phase 1 study of REGN5837 in people with relapsed or refractory B-cell non-Hodgkin lymphomas

Trial

… called odronextamab in patients with relapsed or refractory B-NHLs. It is aiming to look at the side effects, … drug called odronextamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs). … 1: A phase 1 study of REGN5837 in people with relapsed or refractory B-cell non-Hodgkin lymphomas …

STP938: A phase 1/2 study of STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas

Trial

… which has returned (relapsed) or not responded to (refractory) two previous treatments may be eligible for this … back (relapsed) or not responded to previous treatment (refractory lymphoma). You can share the following … A phase 1/2 study of STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas …